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The diagnosis of parathyroid carcinoma requires an invasive growth pattern or metastases detected at histopathological
examination; unfortunately, not all carcinomas exhibit visible malignant properties at the initial assessment. Therefore,
immunohistochemical markers have been sought for the recognition of parathyroid malignancy. In 2003, the Hyperparathyroidism
2( H R P T 2 )gene was found mutated in the majority of sporadic parathyroid carcinomas investigated, and studies regarding the
protein product paraﬁbromin proposed loss of nuclear paraﬁbromin as a highly sensitive marker for the detection of parathyroid
carcinoma. Recent studies have not fully reproduced these ﬁndings, as subsets of carcinomas display positive paraﬁbromin
immunoreactivity, and fractions of adenomas demonstrate absent expression. Overall, paraﬁbromin is a marker of value to the
endocrine pathologist, but it cannot be recommended as a sole indicator of parathyroid carcinoma. Additional markers such
as protein gene product 9.5 (PGP9.5) and adenomatous polyposis coli (APC) could complement paraﬁbromin when assessing
malignant potential of parathyroid tumours.
1.Introduction
Primary hyperparathyroidism (PHPT) originating from a
parathyroidcarcinomaisaninfrequentﬁndingintheclinical
setting. Clinical manifestations indicative of parathyroid
carcinoma include profound hypercalcemia with severe
metabolic disease and a palpable mass in the anterior neck
region [1]. Histopathological features such as nuclear atypia,
macronucleoli, ﬁbrous bands splitting the parenchyma,
trabecular growth, and elevated mitotic counts are common
ﬁndings in parathyroid carcinomas, but are also found in
various proportions of parathyroid benign tumours [2].
Although the above-mentioned observations might suggest
parathyroid carcinoma, the deﬁnite diagnosis is based on
the histopathological identiﬁcation of malignant proper-
ties such as vascular or perineural invasion, alternatively
direct spread into surrounding local tissues, as well as the
observation of distant metastases [3]. The diagnosis of
parathyroid carcinoma cannot be established at preoperative
investigation, since ﬁne needle cytology should be avoided
if a malignant parathyroid lesion is suspected. Furthermore,
the diagnosis cannot easily be established interoperatively by
frozen section analysis due to the suboptimal morphology
obtained. Instead, the deﬁnite diagnosis is either made
at routine histopathological examination after the initial
parathyroidectomy,oryearsaftertheinitialsurgerywhenthe
patient presents with clinical manifestations of metastases. If
diagnoseddirectlypostoperatively,thetreatingphysiciansare
often obliged to choose between an aggressive reoperation
and vigilant followup.
Optimally, the diagnosis of a malignant tumour is
made prior to the onset of advanced malignant properties
so that the tumour can be radically removed before an
eventual metastatic spread. Extensive research has, there-
fore, been conducted to identify a potential molecular
marker which could discriminate between malignant and
benign parathyroid tumours prior to the onset of required
histopathological requirements. Early studies focused on
immunohistochemical analyses of well-established proteins
controlling the cell cycle process as well as apoptosis, such2 International Journal of Endocrinology
as the retinoblastoma protein (pRb), p53, and cyclin D1 [4–
6]. Although initially promising, subsequent studies have
reported substantial overlap between malignant and benign
tumours, thereby reducing the overall speciﬁcity of the
method for each of these proteins [7–9]. The proliferation
marker Ki-67 has also been implicated as an adjunct tool,
since parathyroid carcinomas generally have greater Ki-67
counts than adenomas [10]. Although an overlap between
the two groups exists, the current WHO classiﬁcation
guidelines concerning parathyroid carcinoma suggests that
tumours with Ki-67 counts greater than 5% should be
subject to closer followup due to an increased risk of
malignancy [3, 7].
In 2002, Carpten et al. demonstrated that the hyper-
parathyroidism-jaw tumour (HPT-JT) syndrome is caused
by a germline mutation in the tumour suppressor gene
Hyperparathyroidism 2 gene (HRPT2), located at 1q25-q31
[11]. Interestingly, a subset of HPT-JT kindred develops
malignant parathyroid tumours, and subsequent analyses
of sporadic parathyroid tumours identiﬁed somatic HRPT2
mutations in the majority of malignant cases examined [12,
13]. This is opposed to the ﬁndings in adenomas, where
HRPT2 mutations only have been detected in small subsets
of cases [11]. HRPT2 encodes a ∼60kDa protein termed
paraﬁbromin, a protein which bears sequence resemblance
with the yeast protein Cdc73 [11]. Just like its yeast coun-
terpart, paraﬁbromin has been shown to be a member of
the polymerase associated factor 1 (PAF1) complex involved
in histone ubiquitination and methylation, resulting in
chromatin remodeling which in turn acts as a regulatory
mechanism of gene transcription [14, 15]. In addition,
paraﬁbromin has been endowed with tumour-suppressive
functions such as inducing apoptosis, inhibiting G1 to S
phase transition of the cell cycle, regulating the wingless
type (Wnt) canonical pathway, as well as directly regulating
growth factor gene expression by binding to their gene
promoters [16–19] (Figure 1). It is, therefore, expected that
lossofnuclearparaﬁbrominthroughmutationalinactivation
of HRPT2 will augment cellular proliferation. Following
the initial discovery of inactivating HRPT2 mutations in
parathyroid carcinomas, studies were launched with the aim
of characterizing paraﬁbromin expression in parathyroid
tumours. In the ﬁrst study published by Tan et al. in
2004, the authors constructed a monoclonal paraﬁbromin
antibody (2H1) and investigated a large number of tumours
for paraﬁbromin expression using immunohistochemistry
[20]. The authors observed complete absence or focal
loss (mixed pattern of positive and negative nuclei) of
paraﬁbromin nuclear immunoreactivity in the vast majority
of parathyroid carcinomas. The ﬁndings resulted in an
overall 96% sensitivity and 99% speciﬁcity in diagnosing
parathyroid carcinoma using paraﬁbromin, as the 48 spo-
radic adenomas investigated exhibited retained expression.
The study also implemented 9 adenomas from HPT-JT
kindred with established HRPT2 mutations; 6 (67%) of
these cases displayed total loss and 2 cases exhibited focal
loss (22%) whereas one case was positive for paraﬁbromin
expression (11%). These ﬁndings suggest that the absence

















Figure 1: Schematic overview regarding paraﬁbromin functions.
Paraﬁbromin is a tumour-suppressor protein which regulates
apoptosis, cell-cycle transition, growth factor gene expression (such
as insulin-like growth factors I and II), the tumour-associated
wingless type (Wnt) pathway, as well as the polymerase associated
factor 1 (PAF1) complex. Loss of paraﬁbromin expression through
mutational inactivation of the HRPT2 gene could in theory aﬀect
one or several of these molecular branches, which in turn would
propagate parathyroid tumorigenesis.
HRPT2 mutations, which is further supported by the loss
of paraﬁbromin expression in the majority of carcinomas,
a group known to frequently carry HRPT2 inactivating
mutations.
The ﬁndings of Tan et al. were conﬁrmed by an indepen-
dentstudyfromAustralia,inwhichtheauthorsemployedthe
2H1 antibody and observed loss of paraﬁbromin immunore-
activity in the majority of sporadic carcinomas (8/11; 73%)
and HPT-JT-related tumours (3/4; 75%) as opposed to
positive staining in benign tumours [21]. The sensitivity was
lower (76%) as opposed to 96% in the previous study of
Tan et al., and one of the reasons for this divergence was
due to the fact that Gill et al. only classiﬁed cases with
complete absence of nuclear immunoreactivity as negative
whereas cases with “weak staining” (similar to the term
“focal loss” proposed by Tan et al.) were categorized as
positive. Although reducing the overall sensitivity for the
detection of parathyroid carcinomas, the authors state that
this system was selected to lessen the rate of interobserver
error when interpreting a case with focal loss. As a result,
the authors advocate that complete absence of paraﬁbromin
nuclear immunoreactivity is diagnostic for a parathyroid
carcinoma or an HPT-JT-related tumour in the presence
of positive internal controls. The authors conclude that the
phenomenon of focal loss warrants further studies before it
can be implemented in the diagnostic arsenal [21].
In a subsequent study, the authors assessed paraﬁbromin
immunoreactivity in a set of parathyroid tumours usingInternational Journal of Endocrinology 3
monoclonal and polyclonal paraﬁbromin antibodies target-
ing diverse epitopes scattered across the protein, including
the previously used monoclonal paraﬁbromin antibody 2H1
[22]. Reduced paraﬁbromin expression was observed in the
majority of parathyroid carcinomas whereas all adenomas
displayed positive nuclear immunoreactivity. The results
were comparable using all four paraﬁbromin antibodies, and
peptide neutralization assays conﬁrmed the speciﬁcity of
the obtained signals. Out of the 15 carcinoma cases with
reduced or absent paraﬁbromin immunoreactivity, only one
sampledisplayedcompleteabsenceofexpressionwhereasthe
remaining 14 cases exhibited partial loss (similar to the term
“focal loss” proposed by Tan et al.) Interestingly, 3 out of 6
cases with established HRPT2 mutations displayed positive
paraﬁbromin expression, suggesting that cases with HRPT2
aberrations, not as a rule, display alterations in paraﬁbromin
immunoreactivity [22].
The discussion regarding the value of paraﬁbromin as
a discriminating marker took a new turn when a sub-
sequent study showed excellent correlations between loss
of paraﬁbromin expression and HRPT2 gene mutations in
which 21/22 sporadic adenomas were paraﬁbromin posi-
tive whereas all 11 carcinomas were negative for paraﬁ-
bromin immunoreactivity using the 2H1 antibody [23].
The paraﬁbromin-negative adenoma and all carcinomas
displayed truncating HRPT2 gene mutations. To counter
these ﬁndings, another group has since detected positive
paraﬁbromin expression in the majority of parathyroid
carcinomas stemming from secondary hyperparathyroidism
[24], and an additional study only observed complete loss of
paraﬁbromin expression in a third of parathyroid carcinoma
specimens examined [25].
2. Discussion
HRPT2 gene aberrancies play an important role in the pro-
gression of parathyroid malignancy, and HRPT2 inactivating
mutations have been established as a major event in sporadic
parathyroid carcinomas [12, 13]. Subsequent studies regard-
ing paraﬁbromin expression in parathyroid tumours have
reached consensus in that sense that a majority of parathy-
roid carcinomas display reduced or absent immunoreactivity
as compared to normal parathyroid tissue or parathyroid
adenomas [20–23, 25]. Therefore, the sensitivity for the
method is validated and should be considered as quite high.
The speciﬁcity seems to be exceptionally high, based on the
ﬁndings of positive nuclear expression in the vast majority
of parathyroid adenomas investigated. However, the overall
speciﬁcity unfortunately does not seem to reach 100%, as a
small fraction of seemingly sporadic, parathyroid adenomas
withoutsignsofatypiaorrelapsingdiseaseapparentlyharbor
HRPT2 gene mutations and absent paraﬁbromin expression
usingWesternblotanalysisaswellasimmunohistochemistry
[26]. Although these adenomas were shown to exhibit
cystic features, a feature commonly observed in the HPT-
JT syndrome, the lack of germline HRPT2 gene alterations
in these cases suggest that they have evolved sporadically.
In addition, independent studies have also demonstrated
reduced paraﬁbromin immunoreactivity and/or HRPT2
mutations in a few cases of sporadic, parathyroid adenomas
[23, 27]. These ﬁndings imply that HRPT2 mutations and
downregulation of paraﬁbromin are present in very small
subgroups of parathyroid benign tumours.
Since parathyroid carcinomas are so uncommonly
observed in the clinical settings as opposed to parathy-
roid adenomas, paraﬁbromin immunohistochemistry will
require almost near-perfect speciﬁcity to reduce the num-
ber of false positive cases. With the currently reported
speciﬁcity, even a few parathyroid adenomas with nega-
tive paraﬁbromin staining will outrank the “true” paraﬁ-
bromin negative cases in the infrequently encountered
carcinoma group. As a consequence, loss of paraﬁbromin
immunoreactivity could either imply parathyroid ade-
noma or carcinoma, but may also indicate an underlying
HRPT2 gene mutation [22]. Positive expression, however,
strongly suggests a benign tumour. Given the fact that
subsets of patients with seemingly sporadic parathyroid
carcinoma have been found to carry germline inactivat-
ing mutations of the HRPT2 gene [13], an observation
of reduced paraﬁbromin expression in a tumour sample
could motivate HRPT2 mutation analysis in the aﬄicted
patient to exclude a possible hereditary background. This
demonstrates one of the main beneﬁts of utilizing paraﬁ-
bromin immunohistochemistry as a marker in the clinical
context.
Another issue regarding paraﬁbromin immunohisto-
chemistry stems from the diﬀerent staining patterns detected
when analyzing parathyroid malignant tumours. Variations
in the number of tumour cells with paraﬁbromin expres-
sion vary between studies, with authors reporting total
absence as well as a mixed pattern of positive and negative
nuclei in addition to 100% positive nuclei in diﬀerent
proportions. For example, Gill et al. classiﬁed parathyroid
tumours with focal loss as positive and, therefore, only
approved a total absence of paraﬁbromin immunoreactivity
as diagnostic of malignancy [21]. However, in independent
studies, approximately half of the parathyroid carcinomas
analyzed displayed reduced expression rather than total
absence of paraﬁbromin, and the authors suggest that
reduced expression of paraﬁbromin as well as total absence
of immunoreactivity indicates malignancy [20, 22]. The
observed discrepancies between the staining patterns could
possibly be explained by diﬀerences in the sample selection
process, as some groups analyze carcinomas based on the
WHO histopathological criteria and others based on bio-
logical evidence of malignant behavior (recurrences, metas-
tases) [20–22]. Diﬀerences in the immunohistochemical
methodology should also be considered, since paraﬁbromin
immunohistochemistry is inﬂuenced by a number of factors,
including antigen retrieval time, antibody dilution, antibody
incubation time, and type of antibody [22]. Another factor
which might complicate the interpretation of paraﬁbromin
immunohistochemistry is the notion that a fraction of
the established HRPT2 germline and somatic mutations
is of missense type rather than the more commonly
observed nonsense or frameshift types [28]. Missense muta-
tions would theoretically produce full-length paraﬁbromin4 International Journal of Endocrinology
although functionally defective. Therefore, it would seem
possible to obtain positive paraﬁbromin immunoreactivity
in subsets of HRPT2 mutated cases if the antibody is
not targeting the epitope of the corresponding missense
alteration.
As a result of the reduced sensitivity and speciﬁcity
of paraﬁbromin as well as the diﬀerent staining patterns
observed, additional molecular markers have been assessed
to complement paraﬁbromin in the screening process. For
example, protein gene product 9.5 (PGP9.5), encoded by
the ubiquitin carboxyl-terminal esterase L1 (UCHL1)g e n e
has been shown to be upregulated in the majority of
parathyroid carcinomas based on gene expression proﬁling,
and the results were veriﬁed by immunohistochemistry
[29]. When analyzing a large number of parathyroid
carcinomas, positive staining for PGP9.5 was shown to
bear a greater sensitivity for the detection of malignant
behavior compared to that of paraﬁbromin, while main-
taining the high speciﬁcity. Another study suggested the
implementation of the Wnt pathway tumour-suppressor
adenomatous polyposis coli (APC) as an additional marker
for the detection of parathyroid carcinoma, as negative
immunoreactivity was demonstrated in 9 out of 12 parathy-
roid carcinomas whereas the expression was retained in
a l la d e n o m a si n v e s t i g a t e d[ 30]. Subsequent APC analyses
on HRPT2 mutated parathyroid adenomas with loss of
paraﬁbromin expression have shown that APC is uni-
formly expressed in these tumours, thereby demonstrating
a superior speciﬁcity which potentially could be of clinical
use [31]. In addition, galectin-3 and human telomerase
reverse transcriptase (hTERT) constitute two other markers
of promising value which could be of clinical importance
when assessing parathyroid tumours of uncertain malignant
potential [32, 33].
In present time, several pathology departments are
known to habitually perform paraﬁbromin immunohisto-
chemistry for parathyroid tumours which are not clearly
benign or that display atypical ﬁndings at the histopatho-
logical examination. Positive paraﬁbromin expression clearly
points towards benign disease, and reduced paraﬁbromin
immunoreactivity should probably indicate intensiﬁed fol-
lowup, since this pattern is often encountered in parathy-
roid malignant disease. In addition, reduced paraﬁbromin
expressioncouldindicateHRPT2geneaberranciesthatcould
motivategermlineHRPT2testingtoexcludepossiblefamilial
disease. However, no clear consensus exists on how the
diﬀerent staining results should be interpreted (reduced
expression versus total loss) as well as how this interpretation
shouldinﬂuencetheoveralltreatmentoftheaﬄictedpatient.
Given the current literature, routine histopathology com-
bined with immunohistochemical analysis of paraﬁbromin
cannot alone be recommended as a deﬁnite screening
method for parathyroid malignancy, but should probably
be regarded as an aiding tool for the pathologist when
assessing parathyroid tumours which are not clearly benign.
Additional discovered or yet undiscovered markers are
likely to increase the sensitivity and speciﬁcity for the
proper recognition of parathyroid carcinomas in the clinical
setting.
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